FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029482922> ?p ?o ?g. }

• W2029482922 endingPage "1503" @default.
• W2029482922 startingPage "1503" @default.
• W2029482922 abstract "<b><i>Objective:</i></b> To determine the incidence of psychiatric adverse events associated with vigabatrin therapy, we reviewed data from US and non-US double-blind, placebo-controlled trials of vigabatrin as add-on therapy for treatment-refractory partial epilepsy. <b><i>Methods:</i></b> “Verbatim” terms from investigators’ reports had been translated into standard “preferred” terms using an adverse event dictionary. Terms for psychiatric events were then combined into categories for analysis of rates during vigabatrin versus placebo treatment. <b><i>Results:</i></b> Compared with placebo, vigabatrin subjects had a higher incidence of events coded as depression (12.1% versus 3.5%, <i>p</i> < 0.001) and psychosis (2.5% versus 0.3%, <i>p</i> = 0.028); there were no significant differences between treatment groups for aggressive reaction, manic symptoms, agitation, emotional lability, anxiety, or suicide attempt. Although depression and psychosis were typically observed during the first 3 months, most studies were 12 to 18 weeks long, so that definitive conclusions could not be reached about timing of events. Psychosis was generally transient and reported to be responsive to reduction or discontinuation of vigabatrin or to neuroleptic treatment. Depression was typically mild. Serious depression, defined as discontinued from the study, hospitalized, or suicide attempt, or coded as psychotic depression, occurred in only 9 of the 49 vigabatrin-treated patients with depression. <b><i>Conclusions:</i></b> Vigabatrin use in treatment-refractory partial epilepsy is associated with increased occurrence of depression and of psychosis, although the frequency of psychosis is apparently lower than previously reported. Clinical experience suggests that these adverse events respond to reduction of vigabatrin dose or to counteractive psychotropic treatment." @default.
• W2029482922 created "2016-06-24" @default.
• W2029482922 creator A5005470710 @default.
• W2029482922 creator A5058610449 @default.
• W2029482922 date "1999-10-22" @default.
• W2029482922 modified "2023-09-30" @default.
• W2029482922 title "Psychiatric adverse events during vigabatrin therapy" @default.
• W2029482922 cites W1973304036 @default.
• W2029482922 cites W1975482049 @default.
• W2029482922 cites W1989441245 @default.
• W2029482922 cites W2016088645 @default.
• W2029482922 cites W2043354111 @default.
• W2029482922 cites W2052509571 @default.
• W2029482922 cites W2055960550 @default.
• W2029482922 cites W2058040795 @default.
• W2029482922 cites W2069134697 @default.
• W2029482922 cites W2070403944 @default.
• W2029482922 cites W2077676499 @default.
• W2029482922 cites W2082808209 @default.
• W2029482922 cites W2085059524 @default.
• W2029482922 cites W2095185628 @default.
• W2029482922 cites W2101700069 @default.
• W2029482922 cites W2114390763 @default.
• W2029482922 cites W2296071420 @default.
• W2029482922 cites W3995885 @default.
• W2029482922 doi "https://doi.org/10.1212/wnl.53.7.1503" @default.
• W2029482922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10534259" @default.
• W2029482922 hasPublicationYear "1999" @default.
• W2029482922 type Work @default.
• W2029482922 sameAs 2029482922 @default.
• W2029482922 citedByCount "99" @default.
• W2029482922 countsByYear W20294829222012 @default.
• W2029482922 countsByYear W20294829222013 @default.
• W2029482922 countsByYear W20294829222014 @default.
• W2029482922 countsByYear W20294829222015 @default.
• W2029482922 countsByYear W20294829222016 @default.
• W2029482922 countsByYear W20294829222017 @default.
• W2029482922 countsByYear W20294829222018 @default.
• W2029482922 countsByYear W20294829222019 @default.
• W2029482922 countsByYear W20294829222020 @default.
• W2029482922 countsByYear W20294829222021 @default.
• W2029482922 countsByYear W20294829222022 @default.
• W2029482922 countsByYear W20294829222023 @default.
• W2029482922 crossrefType "journal-article" @default.
• W2029482922 hasAuthorship W2029482922A5005470710 @default.
• W2029482922 hasAuthorship W2029482922A5058610449 @default.
• W2029482922 hasConcept C118552586 @default.
• W2029482922 hasConcept C120665830 @default.
• W2029482922 hasConcept C121332964 @default.
• W2029482922 hasConcept C126322002 @default.
• W2029482922 hasConcept C139719470 @default.
• W2029482922 hasConcept C142424586 @default.
• W2029482922 hasConcept C142724271 @default.
• W2029482922 hasConcept C15744967 @default.
• W2029482922 hasConcept C162324750 @default.
• W2029482922 hasConcept C187212893 @default.
• W2029482922 hasConcept C197934379 @default.
• W2029482922 hasConcept C204787440 @default.
• W2029482922 hasConcept C27081682 @default.
• W2029482922 hasConcept C2775858608 @default.
• W2029482922 hasConcept C2776867660 @default.
• W2029482922 hasConcept C2778186239 @default.
• W2029482922 hasConcept C2778715236 @default.
• W2029482922 hasConcept C2779727114 @default.
• W2029482922 hasConcept C2780163958 @default.
• W2029482922 hasConcept C2780837902 @default.
• W2029482922 hasConcept C558461103 @default.
• W2029482922 hasConcept C61511704 @default.
• W2029482922 hasConcept C71924100 @default.
• W2029482922 hasConcept C87355193 @default.
• W2029482922 hasConceptScore W2029482922C118552586 @default.
• W2029482922 hasConceptScore W2029482922C120665830 @default.
• W2029482922 hasConceptScore W2029482922C121332964 @default.
• W2029482922 hasConceptScore W2029482922C126322002 @default.
• W2029482922 hasConceptScore W2029482922C139719470 @default.
• W2029482922 hasConceptScore W2029482922C142424586 @default.
• W2029482922 hasConceptScore W2029482922C142724271 @default.
• W2029482922 hasConceptScore W2029482922C15744967 @default.
• W2029482922 hasConceptScore W2029482922C162324750 @default.
• W2029482922 hasConceptScore W2029482922C187212893 @default.
• W2029482922 hasConceptScore W2029482922C197934379 @default.
• W2029482922 hasConceptScore W2029482922C204787440 @default.
• W2029482922 hasConceptScore W2029482922C27081682 @default.
• W2029482922 hasConceptScore W2029482922C2775858608 @default.
• W2029482922 hasConceptScore W2029482922C2776867660 @default.
• W2029482922 hasConceptScore W2029482922C2778186239 @default.
• W2029482922 hasConceptScore W2029482922C2778715236 @default.
• W2029482922 hasConceptScore W2029482922C2779727114 @default.
• W2029482922 hasConceptScore W2029482922C2780163958 @default.
• W2029482922 hasConceptScore W2029482922C2780837902 @default.
• W2029482922 hasConceptScore W2029482922C558461103 @default.
• W2029482922 hasConceptScore W2029482922C61511704 @default.
• W2029482922 hasConceptScore W2029482922C71924100 @default.
• W2029482922 hasConceptScore W2029482922C87355193 @default.
• W2029482922 hasIssue "7" @default.
• W2029482922 hasLocation W20294829221 @default.
• W2029482922 hasLocation W20294829222 @default.
• W2029482922 hasOpenAccess W2029482922 @default.

• next